Answers are grounded in this paper and cite their sources.
Background/Objectives: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Small RNA-based therapeutics may provide a means of simultaneously modulating multiple oncogenic pathways. We screened candidate small RNAs for antitumor activity in MPM and investigated the molecular basis of the response to the selected sequence. We aimed to identify a small RNA with reproducible antitumor activity in human mesothelioma cells and to define the signaling and transcriptional programs associated with its activity. Methods: Candidate small RNAs were transfected into three human mesothelioma cell lines (H2052, H2452, and H28). Cell viability and proliferation were assessed by WST-8 and BrdU incorporation assays. Intracellular signaling was examined using dual-luciferase reporters, and RNA sequencing with gene set enrichment analysis (GSEA) was used to characterize transcriptional changes. Results: Among the tested RNAs, the small artificial sequence (SAS) most consistently reduced cell viability and significantly suppressed proliferation in all three cell lines. Untreated mesothelioma cells showed prominent enrichment of E2F Targets compared with normal lung tissue, whereas SAS treatment suppressed E2F-associated cell-cycle programs and significantly reduced BrdU incorporation, consistent with inhibition of G1/S cell-cycle progression. SAS also reduced AP1 and SRE activities in H2452 cells but not in H2052 cells, indicating cell line-dependent modulation of MAPK-related signaling. SAS also induced interferon- and inflammatory response gene sets, with particularly strong cytokine induction observed after phosphorothioate (PS) modification of the passenger strand. Conclusions: SAS exerted reproducible antitumor effects in human mesothelioma cells, with suppression of cell proliferation and E2F-associated cell-cycle programs as the most consistent findings. These results support further investigation of SAS in MPM, although its therapeutic efficacy remains to be established in vivo.
No takes yet. Share an insight, caveat, or question.
Kouda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: